CONCLUSION
In conclusion, co-administered evogliptin and glimepiride had no PK interactions, but exerted an additive glucose lowering effect compared to evogliptin or glimepiride monotherapy. Therefore, the combination therapy with evogliptin and glimepiride may be an alternative option for T2DM patients with inadequate glycemic control using either a DPP-4 inhibitor or sulfonylurea.